NT 3 gene therapy

Drug Profile

NT 3 gene therapy

Alternative Names: Neurotrophin 3 gene therapy

Latest Information Update: 18 Jul 2006

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Gene therapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Motor neuron disease

Most Recent Events

  • 18 Jul 2006 Discontinued - Preclinical for Motor neuron disorders in France (unspecified route)
  • 18 Jul 2006 Discontinued - Preclinical for Motor neuron disorders in Denmark (unspecified route)
  • 07 Oct 2003 A preclinical study has been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top